Amarantus Biosci Inc (AMBS) 0.0582 $AMBS Amarantus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarantus Biosci Inc (AMBS) 0.0582 $AMBS

Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease
GlobeNewswire - Fri May 15, 7:05AM CDT
Collaboration Using Renishaw Plc's Convection-Enhanced Delivery Device Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas

Amarantus BioScience Holdings, Inc. - "MANF Begins its March Towards the Clinic"
ACCESSWIRE - Thu May 14, 12:35PM CDT
NEW YORK, NY / ACCESSWIRE / May 14, 2015 / Amarantus BioScience Holdings, Inc. (PINKSHEETS: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's Independent Director, Joseph Rubinfeld, PhD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

New Collaborations Lead to Advancements in Human Clinical Trials for Development of Clinical Grade Production for Therapeutic Product Candidates With Proprietary Technologies
PR Newswire - Thu May 14, 7:45AM CDT
Therapeutic treatment applications for diseases in the areas of neurology, psychiatry, ophthalmology and regenerative medicine and other rare orphan conditions search for new advancements through continued research and human clinical studies. Specialty Biotech companies in focus today are: Amarantus BioScience Holdings, Inc. (OTC: AMBS), Discovery Laboratories, Inc. (NASDAQ: DSCO), Fibrocell Science, Inc., (NASDAQ: FCSC), OPKO Health, Inc. (NYSE:OPK) and AbbVie Inc. (NYSE: ABBV).
OPK: 16.92 (+0.24), FCSC: 4.02 (+0.01), CTLT: 30.43 (+1.11), ABBV: 65.99 (+0.02), BMY: 67.64 (+0.19), DSCO: 0.96 (+0.04)

Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
GlobeNewswire - Thu May 14, 7:05AM CDT
- Catalent to Utilize Proprietary GPEx Platform for Production of High Performance MANF Expressing Cell Line -
CTLT: 30.43 (+1.11)

Global Traumatic Brain Injury Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9f9f48/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - ALSP, Inc. - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - International Stem Cell Corporation - Io Therapeutics, Inc. - Ischemix - Karyopharm Therapeutics, Inc. - Kyorin Pharmaceutical Co., Ltd. - Levolta Pharmaceuticals, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - MandalMed, Inc. - Mapreg S.A.S. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - PharmatrophiX, Inc. - Phylogica Limited - Prevacus, Inc. - PsychoGenics, Inc. - QR Pharma, Inc. - RAPID Pharmaceuticals AG - RegeneRx Biopharmaceuticals, Inc. - SynZyme Technologies, LLC - Tetra Discovery Partners LLC - vasopharm GmbH - VG Life Sciences, Inc. For more information visit http://www.researchandmarkets.com/research/9f...atic_brain
NBS: 2.38 (+0.07), LPTN: 1.83 (+0.04), CNCE: 14.13 (-0.05), ATHX: 1.27 (-0.01), KPTI: 24.81 (-2.02), CUR: 1.70 (-0.04)

Amarantus receives NOA for patent covering lead product candidate
Seeking Alpha - at Seeking Alpha - Wed May 13, 3:18PM CDT


Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease
GlobeNewswire - Wed May 13, 12:00PM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 11/713,156 entitled, "Pharmacological Treatment of Parkinson's Disease." Upon issuance, the patent will provide additional intellectual property protection for the Company's lead product candidate, eltoprazine. The allowed patent claims cover methods and compositions for the administration of eltoprazine for the alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease.

Amarantus Reports Preliminary Data From Blood-based Version of MSPrecise(R) Diagnostic for Multiple Sclerosis
GlobeNewswire - Mon May 11, 7:35AM CDT
-MSPrecise blood diagnostic shows statistically significant sensitivity and specificity for classifying presentation of multiple sclerosis-

Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire - Thu May 07, 10:15AM CDT
- Study conducted by leading researchers at University of Miami -

Amarantus wins USPTO's Notice of Allowance for patent application covering proprietary compositions of matter and methods for MANF
M2 - Wed May 06, 4:05AM CDT
Biotechnology company Amarantus BioScience Holdings (OtherOTC:AMBS) revealed on Tuesday that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US patent application entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof."

Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
GlobeNewswire - Tue May 05, 7:05AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting Factors and Uses Thereof." Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter and methods of use related to the Company's proprietary manufacturing process for synthetic MANF and its administration.

Latin America, Africa and Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019
M2 - Tue May 05, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/53vpq4/clinical) has announced the addition of the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Latin America, Africa and Middle East Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Latin America, Africa & The Middle East 6. Global Market Summary Companies Mentioned - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/53vpq4/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)

Asia Pacific Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015-2019
M2 - Tue May 05, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v9wvdm/clinical) has announced the addition of the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Asia Pacific Version" report to their offering. A market that just keeps on growing. Clinical laboratory testing is positioned to directly benefit from the explosion in biotechnology, especially genomics. A range of dynamic trends are pushing market growth and company valuations. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Asia Pacific 6. Global Market Summary Companies Mentioned - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/v9wvdm/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)

North America Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015-2019
M2 - Tue May 05, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vlz7vv/clinical) has announced the addition of the "Clinical Laboratory,Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - North American Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Global Market Summary 7. The Future of the Clinical Laboratory Companies featured: Partial List - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/vlz7vv/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)

European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019
M2 - Tue May 05, 5:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b6k9j8/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecasts 2015 to 2019 - Europe Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Markets - Europe 6. Global Market Summary 7. The Future of the Clinical Laboratory Companies Mentioned: Partial List - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/b6k9j8/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)

Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019
M2 - Tue May 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6l9drr/clinical) has announced the addition of the "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 - Global Version" report to their offering. Exciting technical developments especially in the area of molecular diagnostics and pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage. "Clinical Laboratory, Molecular Diagnostic and Genomic Testing Services - 2015 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help sharpen your pricing. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Trends like: - Changing demographics - Emerging economies and global prosperity - Biotechnology advances in genetics - Pathogen evolution - Climate change - Globalization - Automation Key Topics Covered: 1. Introduction and Market Definition 2. Market Overview 3. Market Trends 4. Laboratory, Molecular Diagnostics and Genomic Testing Recent Developments 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. The Future of the Clinical Laboratory Companies Mentioned - Partial List of the 350 Companies Featured - 14M Genomics - 20/20 GeneSystems - 23andMe - 3M - ACM Medical Laboratory - ACT Genomics - AITbiotech - ARUP Laboratories, Inc. - AbVitro - Abbott Diagnostics - Abcam - Accelerate Diagnostics - Acibadem Labmed Laboratory - Adaptive Biotechnologies - Adarza BioSystems - Adicon Clinical Laboratories, Inc. - Advanced Cell Diagnostics - Aegis Sciences - Aeris Capital - Aetna - Aetna Innovation Lab - Agena Bioscience - Agendia - Alberta Investment Management - Alere Inc - Allegro Dx - Alliance Global - AltheaDx - Amarantus BioScience - American Liberty Petroleum For more information visit http://www.researchandmarkets.com/research/6l9drr/clinical
AXDX: 23.08 (-0.05), ALR: 50.75 (+0.36)

BUYINS.NET Updates Amarantus BioSciences (AMBS) SqueezeTrigger Report
M2 - Fri May 01, 6:47AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTC: AMBS) after releasing the latest short sale data through April 30, 2015. The total aggregate number of shares shorted since June 2011 is approximately 1.41 billion shares. Approximately 29.66% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.078. A short squeeze is expected to begin when AMBS is above its SqueezeTrigger Price.

Amarantus human growth factor tagged an Orphan Drug in Europe for retinal disease
Seeking Alpha - at Seeking Alpha - Wed Apr 29, 8:37AM CDT


Orphan Drug Designations Lead to New Therapeutic Breakthroughs for Rare Disorders and Diseases
PR Newswire - Wed Apr 29, 7:45AM CDT
According to a recent article published on the Wall Street Journal, the debate over prescription drug pricing has grown increasingly contentious, particularly as drug makers issue more new medicines with high price tags. But despite the tumult, the cost for orphan drugs - medicines that are designated by the FDA & EU to treat a rare disease and may cost as much as $400,000 annually - is apparently not fazing some insurers. Biotech Companies in focus today are: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Catalyst Pharmaceutical Partners' (NASDAQ: CPRX), Biogen Inc. (NASDAQ: BIIB), Hemispherx Biopharma, Inc. (NYSE: HEB) and Biocept, Inc. (NASDAQ: BIOC).
BIIB: 391.24 (-3.11), CPRX: 3.32 (-0.02), HEB: 0.25 (unch), BIOC: 2.91 (+0.15)

Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
GlobeNewswire - Wed Apr 29, 6:05AM CDT
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug status for MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of retinitis pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness. The Company previously announced in December of 2014 that it also received orphan drug designation for MANF for the treatment of RP from the U.S. Food and Drug Administration (FDA).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 148

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 112

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 188

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Thread AI Joins Microsoft Pegasus: Big AI Leap

Updated Category News Views 26

Thread AI Leaps Ahead with Microsoft Partnership There's excitement in the air as Thread AI joins forces with Microsoft by entering the exclusive Pegasus Program. In the ever-evolving world of AI, making a splash this big doesn't happen every day. People in the tech alley are buzzing, and it looks like Thread AI is ready to rumble on a larger stage—much like a scrappy...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Tackling the Industrialized Beast of Insurance Fraud

Updated Category News Views 86

Stepping Up the Fraud Fight This year's emerging fraud trends are taking the term 'organized crime' to new heights, and it's painting a bullseye on the insurance industry. The National Insurance Crime Bureau (NICB) just laid out how fraud isn't just a series of isolated scams anymore—it's an industrial-scale racket. As they spotlight during International Fraud Awareness...

Continue Reading

Top 5 Most Recently Viewed Articles

Evogene Partners with Academic Leader to Combat Metabolic Disorders

Updated Category News Views 174

Evogene's Innovative Collaboration Evogene Ltd. (NASDAQ: EVGN) has entered into an exciting partnership with Professor Ehud Gazit from Tel Aviv University to develop innovative therapeutics aimed at metabolic diseases. Understanding Metabolic Diseases Metabolic diseases often arise from the inability of the body to break down specific metabolites. This inability can lead...

Continue Reading
Farasis Energy's Rise in Solid-State Battery Rankings Explained

Updated Category News Views 505

Farasis Energy's Notable Achievement in Battery Technology Recently, Farasis Energy gained recognition as a leading contender in the 2024 China Solid-State Battery Competitiveness Rankings, marking a significant milestone in the company's journey. As a global frontrunner in electric vehicle (EV) battery solutions, Farasis Energy has established robust partnerships with...

Continue Reading
Building a Reliable Future with Weilliptic's Advanced AI

Updated Category News Views 310

Weilliptic: Pioneering Autonomous and Trustworthy AI In the rapidly evolving landscape of technology, Avinash Lakshman, a serial entrepreneur renowned for creating Amazon Dynamo and Apache Cassandra, is leading the charge towards a new foundational infrastructure that merges AI and blockchain into a cohesive and verifiable framework. This innovative platform, known as...

Continue Reading
Navigating Investor Rights: Aehr Test Systems Case Insights

Updated Category News Views 169

Aehr Test Systems Investor Rights and Securities Fraud Lawsuit Investors in Aehr Test Systems (NASDAQ: AEHR) find themselves at a critical juncture. The Rosen Law Firm, renowned for its advocacy on behalf of investors, has issued important reminders regarding a securities fraud lawsuit that centers on Aehr Test Systems. Understanding the Class Period The timeline for this...

Continue Reading
Understanding Andersons' Earnings and Market Performance Insights

Updated Category News Views 276

Anticipating Earnings from Andersons Inc Andersons Inc (NASDAQ: ANDE) is gearing up to share its quarterly earnings report soon. This announcement is of considerable interest to both existing shareholders and potential investors. It's vital to stay informed about what to expect before the company reveals its financial results. Projected Earnings and Market Sentiments...

Continue Reading